Education
About Us
Working with TipRanks
Follow Us
Cocrystal Pharma (COCP)
:COCP
COCP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $3.26
Previous CloseN/A
Volume45.82K
Average Volume (3M)27.75K
Market Cap
$17.60M
Enterprise Value$6.69M
Total Cash (Recent Filing)$2.72M
Total Debt (Recent Filing)$331.00K
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Apr 07, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding10,173,790
10 Day Avg. Volume26,397
30 Day Avg. Volume27,748
Standard Deviation0.29
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.44
Enterprise Value/Ebitda-0.35
Forecast
1Y Price Target
$8.50Price Target Upside374.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Cocrystal Pharma News
PremiumCompany Announcements
Cocrystal Pharma Engages Investors with Limited Disclosure
PremiumCompany Announcements
Cocrystal Pharma Reports Positive Phase 1 Study Results
PremiumCompany Announcements
Cocrystal Pharma Extends Enrollment for Influenza Study
PremiumCompany Announcements
Cocrystal Pharma Advances Antiviral Drug Development---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentCocrystal Pharma announced favorable safety and tolerability results at dosage levels of up to 800mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-988.
Drug EfficacyCocrystal has announced that studies of its influenza drug, CC-42344, have shown efficacy against the new avian influenza strain H5N1.
Bears Say
Financial PerformanceCocrystal Pharma reported a 2Q24 net loss of $0.53 per share, moderately wider than the forecast for a net loss of $0.43 per share.
---
Ownership Overview
51.52% Insiders
3.39% Mutual Funds
0.10% Other Institutional Investors
42.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
COCP FAQ
What was Cocrystal Pharma’s price range in the past 12 months?
Cocrystal Pharma lowest stock price was $1.35 and its highest was $3.26 in the past 12 months.
What is Cocrystal Pharma’s market cap?
Cocrystal Pharma’s market cap is $17.60M.
When is Cocrystal Pharma’s upcoming earnings report date?
Cocrystal Pharma’s upcoming earnings report date is Apr 07, 2025 which is in 34 days.
How were Cocrystal Pharma’s earnings last quarter?
Cocrystal Pharma released its earnings results on Nov 13, 2024. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.08.
Is Cocrystal Pharma overvalued?
According to Wall Street analysts Cocrystal Pharma’s price is currently Undervalued.
Does Cocrystal Pharma pay dividends?
Cocrystal Pharma does not currently pay dividends.
What is Cocrystal Pharma’s EPS estimate?
Cocrystal Pharma’s EPS estimate is -0.53.
How many shares outstanding does Cocrystal Pharma have?
Cocrystal Pharma has 10,173,790 shares outstanding.
What happened to Cocrystal Pharma’s price movement after its last earnings report?
Cocrystal Pharma reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went up 0.568%.
Which hedge fund is a major shareholder of Cocrystal Pharma?
Currently, no hedge funds are holding shares in COCP
---
Company Description
Cocrystal Pharma
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.
---
COCP Stock 12 Month Forecast
Average Price Target
$8.50
▲(374.86% Upside)
Technical Analysis
Best Analysts Covering COCP
1 Year
1 Year Success Rate
1/21 ratings generated profit
1 Year Average Return
-39.97%
reiterated a buy rating 2 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 4.76% of your transactions generating a profit, with an average return of -39.97% per trade.
---